Interleukin-6 production by human neonatal monocytes stimulated by type III group B streptococci

Journal of Infectious Diseases

Volumn 174, Issue 2, 1996, Pages 332-337

  Vallejo, Jesus G ^a   Baker, Carol J ^a   Edwards, Morven S ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERLEUKIN 6; LIPOTEICHOIC ACID; STREPTOCOCCUS ANTIGEN;

ADULT; ARTICLE; BACTERIAL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; LEUKOCYTE ACTIVATION; MONOCYTE; NEWBORN; PRIORITY JOURNAL; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; UMBILICAL CORD BLOOD;

EID: 0030003257     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.2.332     Document Type: Article

References (16)

1. Baker CJ, Edwards MS. Group B streptococcal infections. In: Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant. 4th ed. Philadelphia: WB Saunders, 1995:980-1054.
2. Payne NR, Burke BA, Day DL, Christenson TD, Thompson TR, Ferrieri P. Correlation of clinical and pathologic findings in early onset neonatal group B streptococcal infection with disease severity and prediction of outcome. Pediatr Infect Dis J 1988;7:836-47.
3. Saez-Llorens X, McCracken GH Jr. Sepsis syndrome and septic shock in pediatrics: current concepts of terminology, pathophysiology, and management. J Pediatr 1993;123:497-508.
4. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-8.
5. Heumann O, Barras C, Severina A, Glausser MP, Tomasz A. Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun 1994;62:2715-21.
6. Barton BE, Jackson JV. Protective role of interleukin-6 in the lipopolysaccharide-galactosamine septic shock model. Infect Immun 1993;61:1496-9.
7. Bucklin SE, Silverstein R, Morrison DC. An interleukin-6 induced acutephase response does not confer protection against lipopolysaccharide lethality. Infect Immun 1993;61:3184-9.
8. Mancuso G, Tomasello F, Migliardo M, et al. Beneficial effects of interleukin-6 in neonatal mouse models of group B streptococcal disease. Infect Immun 1994;62:4992-5002.
9. Hacks E, De Groot ER, Felt-Bersma RJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989;74:1704-10.
10. Sullivan JS, Kilpatrick L, Costarino AT, Lee SC, Harris MC. Correlation of plasma cytokine elevations with mortality rates in children with sepsis. J Pediatr 1992;120:510-5.
11. Teti G, Mancuso G, Tomasello F, Chiofalo MS. Production of tumor necrosis factor alpha and interleukin-6 in mice infected with group B streptococci. Circ Shock 1992;38:138-44.
12. Teti G, Mancuso G, Tomasello F. Cytokine appearance and effects of anti-tumor necrosis factor alpha in a neonatal rat model of group B streptococcal infection. Infect Immun 1993;61:227-35.
13. Buck C, Bundschu J, Gallati H, Bartman P, Pohlandt F. Interleukin-6: a sensitive parameter for the early diagnosis of neonatal bacterial infection. Pediatrics 1993;93:54-8
14. Sullivan SJ, Kilpatrick L, Costarino AT Jr, et al. Cytokine elevations in infants with bacterial and aseptic meningitis. J Pediatr 1995;126:872-6.
15. Edwards MS, Kasper DL, Jennings HJ, Baker CJ, Nicholson-Weller A. Capsular sialic acid prevents activation of the alternative complement pathway by type III group B streptococci. J Immunol 1982;128:1278-83.
16. Wessels MR, Paoletti LC, Kasper DL, et al. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest 1990;86:1428-33.